Gaetano Rocco

From Top Italian Scientists Wiki
Revision as of 16:16, 9 March 2023 by Admin (talk | contribs)

Gaetano Rocco (born July 15, 1960, Milan, Italy). He is Director, Chest Wall Surgery Program and Attending Surgeon at the MSKCC, New York, NY[1].

Gaetano Rocco
Born
July 15, 1960, Milan, Italy
Nationality
Italian
Education
MD, University of Milan, Italy
Fields
Thoracic Surgery, Translational medicine, Clinical guidelines, Minimally invasive thoracic surgery
Institutions
Director, Chest Wall Surgery Program, MSKCC, New York, NY
Attending Surgeon, MSKCC, New York, NY
Notes
Top Italian Scientist in Clinical Sciences [2]

Education and career

Academic Degree

  • 1985: MD, University of Milan, Italy.

Post-doctoral training =

  • 1984, 1986, 1987-1988: Research Fellow in Surgical Pathology, Stritch School of Medicine, Loyola University, Chicago, IL.
  • 1985-1990: Resident, General Surgery, University of Milan Hospitals, Milan, Italy.
  • 1990-1995: Resident, Thoracic Surgery, University of Milan Hospitals, Milan, Italy.
  • 1995: Visiting Resident, Section of General Thoracic Surgery, Mayo Clinic and Mayo Foundation, Rochester, MN.
  • 1996-1997: Clinical Fellow in Advanced General Thoracic Surgery, Section of General Thoracic Surgery, Mayo Clinic and Mayo Foundation, Rochester, MN.
  • 1999: Fellowship in Laparoscopic Surgery, University of Strasbourg, France, on behalf of the European Institute of Telesurgery (EITS), Strasbourg, France.
  • 2000: Research Fellow, British Mesothelioma Group, British Lung Volume Reduction Group.
  • 2003: Research Fellow, MRC LU-22.

Career

Academic positions

  • 1992: Professor of Surgery, E. Morelli Regional Hospital, Nursing School, Sondalo, Italy.
  • 1993-1999: Professor of Thoracic Surgery, E. Morelli Regional Hospital, Nursing School, Sondalo, Italy.
  • 2000-2004: Hon. Senior Clinical Lecturer, Department of Cardiothoracic Surgery, Northern General Hospital, Sheffield Teaching Hospitals, Sheffield, UK.
  • 2004-2006: Faculty, European School for Cardiothoracic Surgery, Bergamo level II.
  • 2011-2018: Professor of Thoracic Surgery, University of Naples, Italy.
  • 2011-2018: Professor of Cardiothoracic Surgery, University of Naples, Italy.
  • 2012-2018: Professor of Thoracic Surgery University of Bari, Italy.

Hospital positions

  • 1988-1999: Staff Thoracic Surgeon, E. Morelli Regional Hospital, Sondalo, Italy.
  • 2000-2004: Consultant Thoracic Surgeon, Department of Cardiothoracic Surgery, Northern General Hospital, Sheffield Teaching Hospitals, Sheffield, UK.
  • 2004-2018: Chief, Division of Thoracic Surgery, National Cancer Institute, Pascale Foundation, Naples, Italy.
  • 2008-2018: Head, Department of Thoracic Surgery and Oncology, National Cancer Institute, Pascale Foundation, Naples, Italy,
  • 2018-Present: Attending Surgeon, MSKCC, New York, NY.
  • 2021-Present: Director, Chest Wall Surgery Program, MSKCC, New York, NY

Other Employment

  • 1986-1987: Medical Officer, Italian Army.

Research

Clinical Trials

  1. ITACA EudraCT n. 2008-001764-36 “Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer” Start date: 2008 – Institutional co-Principal Investigator.
  2. MILES-3 Cisplatin in Combination With Gemcitabine for Elderly Patients With Stage IIIB-IV Non Small Cell Lung. Role: Surgical Investigator.[3]
  3. MILES-4 Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Elderly Patients With Advanced Nonsquamous Lung Cancer. Role: Surgical Investigator.[3]
  4. PETRA. Study of Metabolic Response measured with PET/CT after the first cycle of chemotherapy in patients with Advanced Non Small Cell Lung Cancer. Role: Surgical Investigator.
  5. ERACLE GOIM Protocol 2903. Induction Pemetrexed and Cisplatin Followed by Pemetrexed as Maintenance vs Carboplatin-paclitaxel and Bevacizumab Followed by Bevacizumab as Maintenance: Multicenter Randomized Phase III Study in Patients With Advanced Non-Squamous Non Small-cell Lung Cancer. Role: Surgical Investigator. [3]

6. ARQ197. A phase 3, randomized, double-blinded, placebo controlled, study of ARQ197 plus

erlotinib versus erlotinib plus placebo in previously treated subjects with locally advanced or

metastatic non-squamous non small cell lung cancer (NSCLC). Role: Surgical Investigator.

www.clinicaltrials.gov

7. INSPIRE. A randomized, multicenter, open-label phase 3 study of pemetrexed-cisplatin

chemotherapy plus IMC-11F8 versus pemetrexed-cisplatin chemotherapy alone in the first line

treatment of patients with non squamous stage IIIB or IV Non-Small Cell Lung Cancer (IMCL CP11-

0805; INSPIRE). Role: Surgical Investigator. www.clinicaltrials.gov

8. SQUIRE. A randomized, multicenter, open-label phase 3 study of gemcitabine-cisplatin

chemotherapy plus IMC-11F8 versus gemcitabine-cisplatin chemotherapy alone in the first line

treatment of patients with squamous stade IIIB or IV Non-Small Cell Lung Cancer (IMCL CP11-0806;

SQUIRE). Role: Surgical Investigator. www.clinicaltrials.gov

9. Phase 2, open label single arm study of the efficacy and safety of PF-02341066 in patients with

advanced non-small cell lung cancer harbouring a translocation or inversion involving the

anaplastic lymphoma kinase (ALK) gene locus. Role: Surgical Investigator

10. Phase 3, randomized open-label study of the efficacy and safety of PF-02341066 versus standard

of care chemotherapy (pemetrexed or docetaxel) in patients with advanced non-small cell lung

cancer harbouring a translocation or inversion involving the anaplastic lymphoma kinase (ALK)

gene locus. Role: Surgical Investigator

11. NCIC CTG BR.26. A double blind placebo controlled trial of PF-804 in patients with incurable stage

IIIB/IV NSCLC after failure of standard therapy for advanced or metastatic disease (NCIC CTG

BR.26). Role: Surgical Investigator. www.clinicaltrials.gov

12. LUX-Lung 8 - A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With

Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line

Platinum-based Chemotherapy. Role: Surgical Investigator. www.clinicaltrials.gov

13. ICARUS. A Phase II Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety

and Tolerability of Gefitinib 250 mg (IRESSA) as 3rd Line Treatment Re-challenge in Patients, Who

Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic

Non-Small Cell Lung Cancer (NSCLC) and Who Responded to Gefitinib in 1st Line and Progressed

After 2nd Line Chemotherapy (Studio ICARUS). Role: Surgical Investigator. www.clinicaltrials.gov

14. AVALL MO22097. An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of

continuous bevacizumab treatment beyond progression of disease (PD) in patients with advanced

non-squamous non-small cell lung cancer (NSCLC) after first (1st)-line treatment with bevacizumab

plus a platinum doublet-containing chemotherapy regimen (AVALL - Roche). Role: Surgical

Investigator

15. ASSESS. A diagnostic Study of European and Japanese advanced NSCLC patients to evaluate

suitable sample types for EGFR testing: The ASSESS Study (Astra Zeneca). Role: Surgical

Investigator. www.clinicaltrials.gov

16. BASALT 2. A Dose-finding phase Ib study followed by a randomized, double-blind phase II study of

carboplatin and paclitaxel with or without buparlisib in patients with previously untreated


References

  1. ↑ Gaetano Rocco - Memorial Sloan Kettering Cancer Center
  2. ↑ Gaetano Rocco - Top Italian Scientist in Clinical Sciences
  3. ↑ 3.0 3.1 3.2 Home - ClinicalTrials.gov
Retrieved from "https://en.wiki.topitalianscientists.org/index.php?title=Gaetano_Rocco&oldid=961"